Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Checked against the public recordLast updated Jan 6, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Revolution Medicines, Inc.
- Interventions being studied
- Drug: RMC-4630; Drug: Sotorasib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subject must be ≥18 years of age. * Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed) Exclusion Criteria * Primary central nervous system (CNS) tumors * Known or suspected leptomeningeal or brain metastases or spinal cord compression * Clinically significant cardiac disease * Known impairment of GI function that would alter the absorption * Active autoimmune disease requiring systemic treatment within past 2 years * History of severe allergic reactions to any of the study intervention components * Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment. * Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Florida Cancer SpecialistsFort Myers, Florida
- BRCR Medical Center Inc.Plantation, Florida
- Cancer Specialists of North FloridaSaint Augustine, Florida
- GenHarp Clinical SolutionsEvergreen Park, Illinois
- Hematology Oncology ClinicBaton Rouge, Louisiana
- New England Cancer SpecialistsScarborough, Maine
- American Oncology Partners of Maryland, PABethesda, Maryland
- Maryland Oncology Hematology, P.A.Columbia, Maryland
- Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
- Nebraska Cancer SpecialistsOmaha, Nebraska
- Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
- New Jersey Center for Cancer ResearchBrick, New Jersey
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 6, 2026. Always confirm current availability with the study team.